Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Managing Patients on Lenvatinib/Everolimus in mRCC

July 30th 2018

Lenvatinib and Everolimus in Relapsed/Refractory mRCC

July 30th 2018

Second-Line Combination Therapy in mRCC

July 30th 2018

Making Decisions for Second-Line Therapy in mRCC

July 30th 2018

Antiangiogenic Resistance in mRCC

July 30th 2018

Bevacizumab and Interferon in mRCC

July 30th 2018

Nivolumab and Ipilimumab in mRCC

July 30th 2018

Cabozantinib in mRCC

July 30th 2018

Rationale for Combination Therapy in mRCC

July 30th 2018

Historical Perspectives on the Treatment of mRCC

July 30th 2018

Choueiri Reflects on Recent RCC Advances

July 26th 2018

Toni K. Choueiri, MD, discusses some of the most significant data presented thus far in 2018 for the treatment of patients with renal cell carcinoma.

Novel Combinations Advance Through RCC Pipeline

July 20th 2018

Peter J. Van Veldhuizen, MD, discusses available and emerging therapies for patients with kidney cancer.

Dr. O'Neil on Emerging Therapeutic Techniques in Bladder Cancer

July 20th 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging therapeutic techniques in bladder cancer.

Dr. Markman on Latest Advances in Treatment of Gynecological Malignancies

July 18th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.

Dr. Agarwal on Frontline Treatment in Kidney Cancer

July 18th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses his preferred frontline treatment for patients with kidney cancer.

Galsky Discusses Ongoing Combination Immunotherapy Trials in Bladder Cancer

July 13th 2018

Matthew Galsky, MD, discusses the IMvigor130 and CheckMate-901 studies, as well as the future for chemotherapy in bladder cancer.

Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney Cancer

July 13th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.

Drake Discusses CARMENA Trial and Emerging Approaches in RCC

July 13th 2018

Charles G. Drake, MD, PhD, discusses the importance of the CARMENA results, the future of cytoreductive nephrectomy, and how the use of immunotherapy could change treatment in this setting.

Evolving Treatment Landscape of Renal Cell Carcinoma

July 11th 2018

Considerations for Using Adjuvant Therapy in mRCC

July 11th 2018